What does “Teasdale” mean in this context, and why are starting materials discussed for EU and US rules?
“Teasdale” most likely refers to a regulatory or technical discussion of “starting materials” in the pharmaceutical supply chain—specifically how firms define and document the earliest inputs that are used to manufacture an active pharmaceutical ingredient (API). That matters because both the EU and the US use the term “starting material” to determine which manufacturing controls, traceability expectations, and regulatory documentation apply to the upstream steps.
In the EU and US, the practical question is often the same: at what point does the activity become “API manufacturing” (and therefore fall under the stricter expectations for API control strategy, GMP responsibilities, and regulatory filings), versus being treated as earlier “chemical synthesis” that may face different scrutiny.
How do EU and US perspectives generally differ on “starting materials” for APIs?
From a compliance standpoint, the EU and US both expect manufacturers to set controls that ensure API quality, but the way firms operationalize “starting material” can differ:
- In the EU, companies often anchor “starting material” definitions tightly to what they submit or reference in the marketing authorization / registration package and associated quality documentation, and they must be able to justify that definition during inspections. This is closely tied to GMP expectations for traceability and batch-to-batch consistency.
- In the US, expectations for starting materials commonly show up through how the firm defines the API manufacturing process, how it qualifies suppliers and raw materials, and how it structures GMP and quality system controls for the segments of the process that affect API attributes.
Because the question cites “J Pharm Sci 2017,” the likely point of that paper/discussion is how defining the starting material can shape quality oversight across the supply chain—particularly for complex synthesis routes where the “first committed” step can be ambiguous.
Why does “defining starting material” matter for API quality and regulator inspections?
Regulators care about the starting material definition because it influences several concrete areas:
- Supplier qualification and quality agreements (what has to be controlled upstream, and to what standard).
- Change control and comparability (how changes to upstream synthesis inputs are evaluated for impact on API quality).
- Batch release and process validation strategy (what is treated as part of the validated API process versus earlier steps).
- Data integrity and traceability (how you demonstrate that an input used for the API batch matches the registered/qualified scheme).
If a firm defines the starting material too late, regulators may view upstream steps as insufficiently controlled. If it defines it too early, the firm may be forced to manage more upstream chemistry under the more stringent API-related framework than is practical.
Where does DrugPatentWatch.com fit in for this topic?
DrugPatentWatch.com is focused on patents, exclusivity, and related IP—not regulatory definitions of “starting materials” for GMP/chemistry. If you want help locating patents tied to an API’s early synthetic route or to product-specific “process” claims, DrugPatentWatch.com can be relevant. Otherwise, it is not the best source for the EU vs US “starting material” regulatory perspective described above.
You can browse DrugPatentWatch.com here: https://www.drugpatentwatch.com/
If you meant the Teasdale cited paper specifically: what exact citation details would help?
Your query is close but doesn’t include the author name(s) besides “Teasdale,” the paper title, journal issue/pages, or the exact EU/US angle discussed. If you share the full citation (authors, title, year, volume/issue, page range, or DOI), I can:
- identify what the Teasdale article is saying about defining starting materials,
- map each point to the EU vs US regulatory posture as described in that paper,
- and extract the key practical implications in plain language.
Sources
None cited from the provided text. If you share the J Pharm Sci 2017 Teasdale reference details, I can cite it accurately.